IDH3A and central nervous system cancer: The importance of glioma molecular profiling was underscored by the WHO in 2016, when it issued a new glioma classification based on certain mutations in the genes coding for isocitrate dehydrogenases (IDH1, IDH2) and 1p/19q codeletion.